Smith Group Asset Management’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-1,970
| Closed | -$35K | – | 349 |
|
|
2020
Q2 | $35K | Sell |
1,970
-20
| -1% | -$278 | ﹤0.01% | 221 |
|
|
2020
Q1 | $14K | Hold |
1,990
| – | – | ﹤0.01% | 307 |
|
|
2019
Q4 | $48K | Hold |
1,990
| – | – | ﹤0.01% | 282 |
|
|
2019
Q3 | $53K | Hold |
1,990
| – | – | ﹤0.01% | 276 |
|
|
2019
Q2 | $54K | Hold |
1,990
| – | – | ﹤0.01% | 269 |
|
|
2019
Q1 | $69K | Sell |
1,990
-5,600
| -74% | -$162K | ﹤0.01% | 283 |
|
|
2018
Q4 | $148K | Sell |
7,590
-510
| -6% | -$10.5K | 0.01% | 266 |
|
|
2018
Q3 | $216K | Buy |
8,100
+2,740
| +51% | +$89.5K | 0.01% | 246 |
|
|
2018
Q2 | $202K | Hold |
5,360
| – | – | 0.01% | 252 |
|
|
2018
Q1 | $175K | Sell |
5,360
-4,100
| -43% | -$180K | 0.01% | 263 |
|
|
2017
Q4 | $461K | Hold |
9,460
| – | – | 0.01% | 214 |
|
|
2017
Q3 | $511K | Hold |
9,460
| – | – | 0.02% | 216 |
|
|
2017
Q2 | $531K | Hold |
9,460
| – | – | 0.02% | 211 |
|
|
2017
Q1 | $371K | Buy |
+9,460
| New | +$301K | 0.01% | 207 |
|
|
2016
Q4 | – | Sell |
-9,670
| Closed | -$220K | – | 499 |
|
|
2016
Q3 | $220K | Hold |
9,670
| – | – | 0.01% | 244 |
|
|
2016
Q2 | $228K | Sell |
9,670
-200
| -2% | -$4.94K | 0.01% | 239 |
|
|
2016
Q1 | $201K | Sell |
9,870
-70
| -0.7% | -$2.22K | 0.01% | 222 |
|
|
2015
Q4 | $511K | Buy |
+9,940
| New | +$482K | 0.02% | 202 |
|
|
2014
Q3 | – | Sell |
-49,170
| Closed | -$1.44M | – | 438 |
|
|
2014
Q2 | $1.44M | Buy |
+49,170
| New | +$1.19M | 0.05% | 168 |
|
Smith Group Asset Management's PTLA Position: Q3 2020 in Review
Smith Group Asset Management sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,970 shares — an estimated $35K sold.
Smith Group Asset Management first reported a position in PTLA in Q2 2014 and held it in 19 quarters. The position peaked at $1.44M in Q2 2014. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Smith Group Asset Management reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Smith Group Asset Management sold 1,970 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $35K.
- Smith Group Asset Management first reported a position in Portola Pharmaceuticals, Inc. in Q2 2014 and held it in 19 quarters.
- Smith Group Asset Management's Portola Pharmaceuticals, Inc. position peaked at $1.44M in Q2 2014.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Smith Group Asset Management's 13F filing for Q3 2020, filed 4 Nov 2020.